The use of thyroid supplements to augment antidepressant medication.
Despite methodological flaws that limit conclusions, a considerable database documents the efficacy of triiodothyronine (T3) as an augmentation strategy for response to various classes of antidepressants. One study suggests that T3 and lithium are of comparable efficacy in antidepressant nonresponders. No clear biochemical or clinical predictors of preferential response to T3 have been found. The role of T3 augmentation requires further evaluation, especially with regard to dose and duration.
Joffe
R T
RT
Department of Psychiatry, McMaster University, Hamilton, Ontario.
D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D008094:Lithium / Q000494:pharmacology / Q000627:therapeutic use; D013974:Thyroxine / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014284:Triiodothyronine / Q000494:pharmacology / Q000627:therapeutic use*
D000928:Antidepressive Agents; D014284:Triiodothyronine; D008094:Lithium; D013974:Thyroxine